Outlook Therapeutics (OTLK) Revenue & Revenue Breakdown
Outlook Therapeutics Revenue Highlights
Latest Revenue (Y)
$1.41T
Latest Revenue (Q)
$-1.21M
Outlook Therapeutics Revenue by Period
Outlook Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-09-30 | $1.41T | 100.00% |
| 2024-09-30 | - | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2020-09-30 | - | -100.00% |
| 2019-09-30 | $8.15M | 163.80% |
| 2018-09-30 | $3.09M | -18.99% |
| 2017-09-30 | $3.81M | 27.92% |
| 2016-09-30 | $2.98M | -42.90% |
| 2015-09-30 | $5.22M | -42.34% |
| 2014-09-30 | $9.05M | - |
Outlook Therapeutics generated $1.41T in revenue during NA 2025, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Outlook Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $-1.21M | 1216.09% |
| 2025-09-30 | $-91.79K | -106.10% |
| 2025-06-30 | $1.51M | 100.00% |
| 2025-03-31 | - | 100.00% |
| 2024-12-31 | - | -100.00% |
| 2024-09-30 | $170.12K | 100.00% |
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | -100.00% |
| 2019-09-30 | $5.85M | 902.66% |
| 2019-06-30 | $583.85K | -8.94% |
| 2019-03-31 | $641.14K | -39.97% |
| 2018-12-31 | $1.07M | 38.36% |
| 2018-09-30 | $771.89K | - |
| 2018-06-30 | $771.89K | - |
| 2018-03-31 | $771.89K | - |
| 2017-12-31 | $771.89K | -73.40% |
| 2017-09-30 | $2.90M | 857.35% |
| 2017-06-30 | $303.14K | -0.00% |
| 2017-03-31 | $303.14K | 0.00% |
| 2016-12-31 | $303.14K | -38.75% |
| 2016-09-30 | $494.89K | - |
| 2016-06-30 | $494.89K | -50.26% |
| 2016-03-31 | $994.89K | - |
| 2015-12-31 | $994.89K | 101.03% |
| 2015-09-30 | $494.89K | -61.78% |
| 2015-06-30 | $1.29M | 161.65% |
| 2015-03-31 | $494.89K | -83.14% |
| 2014-12-31 | $2.93M | - |
Outlook Therapeutics generated $-1.21M in revenue during Q1 2026, up 1216.09% compared to the previous quarter, and up -710.07% compared to the same period a year ago.
Outlook Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| OTLK | Outlook Therapeutics | $1.41T | $-1.21M |
| IPSC | Century Therapeutics | $109.16M | - |
| EQ | Equillium | $41.09M | - |
| CUE | Cue Biopharma | $5.49M | $2.95M |
| HOWL | Werewolf Therapeutics | $1.89M | - |
| COEP | Coeptis Therapeutics | - | $62.87K |
| OSTX | OS Therapies | - | - |
| SPRB | Spruce Biosciences | - | - |
| MDCX | Medicus Pharma | - | - |
| IOBT | IO Biotech | - | - |
| NRXP | NRx Pharmaceuticals | - | $242.00K |